Hermann Nabi, PhD, HDR, is a regular researcher in the Oncology division at CHU de Québec-Université Laval Research Center and Assistant Professor of Epidemiology at the Department of Social and Preventive Medicine at the Faculty of Medicine of Université Laval. Prior to joining the Center and Université Laval in 2016, Dr. Nabi headed the Research Department of Social and Human Sciences, Epidemiology, Public Health at the Institut National du Cancer(INCa) and was a regular researcher at l’Institut National de la Santé et de la Recherche Médicale(INSERM U.1018) in France.

His team’s work focuses on precision medicine, this emerging medical approach for disease prevention and treatment that takes into account individual differences in genes, environment and lifestyle for each person. With advances in genomics and the advent of new molecular biology technologies, precision medicine is attracting a lot of attention and has become an area of ​​strong international competition. However, despite the large volume and unprecedented rate of gene or biomarker discoveries, relatively few have reached the bedside or contributed to improving the health of populations. This relative poor performance could be explained by the fact that only a small proportion (about 3%) of all published global research addresses issues related to the integration of genomics innovations into health and disease prevention. For this reason, the ultimate goal of Dr. Nabi’s team is to generate evidence to facilitate a successful and responsible integration of precision medicine innovations into health care and prevention, particularly for cancer.

To achieve this goal, his work is organized around three main objectives:

1) Characterize the mechanisms and organizational implications of the progressive adoption of innovations in precision medicine in oncology,

2) Evaluate the impact of diagnostic and therapeutic innovations in precision medicine on the quality of life and clinical outcomes of cancer patients and the effectiveness for the health system,

3) Develop and evaluate intervention methods to support the integration of innovations, which takes into account patients and populations’ preferences, economic, accessibility and impact issues, in a knowledge transfer perspective.

The originality of this research program lies in its interdisciplinary approach, which combines a variety of skills and methodological tools to answer questions that are at the interface of several scientific fields. This approach proposes a new way of approaching translational research (the transfer of discoveries from laboratory to bedside), through the use of concepts, models and methods  the human and social sciences, epidemiology, public health, health services research and implementation science.

Hôpital Saint-Sacrement
1050, Chemin Ste-Foy
J0-01
Québec, Qc
Canada G1S 4L8
+1 418-525-4444, extension 82800
Hermann.Nabi@crchudequebe...

Latest news

104 entries « ‹ 2 of 11 › »

Villafane-Bernier C, Lapointe J, Raîche C, Lauzier S, Chiquette J, Bouchard K, Pelletier S, Omeranovic A, Rhéaume J, Brousseau C, Hébert J, Dorval M, Nabi H

Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Journal Article

Healthcare (Basel), 9 (9), 2021.

Abstract | Links:

Gagnet S, Diorio C, Provencher L, Mbuya-Bienge C, Lapointe J, Morin C, Lemieux J, Nabi H

Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Pashayan N, Antoniou AC, Lee A, Wolfson M, Chiquette J, Eloy L, Eisen A, Stockley TL, Nabi H, Brooks JD, Dorval M, Easton DF, Knoppers BM, Chiarelli AM, Simard J

Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J

Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)

Journal Article

J Pers Med, 11 (6), 2021.

Abstract | Links:

Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The Perspective I I Study Group , Knoppers BM, Chiarelli AM, Simard J, Joly Y

Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data

Journal Article

J Pers Med, 11 (8), 2021.

Abstract | Links:

Dupin CM, Estaquio C, Nabi H

Theoretical conceptions of intervention research addressing cancer control issues

Journal Article

Health Promot Int, 36 (1), 2021.

Abstract | Links:

Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin JR, Laberge M, Gekas J, Hébert J, Pomey MP, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Bouchard K, Rhéaume J, Boisvert K, Brousseau C, Castonguay L, Fortier S, Gosselin I, Lachapelle P, Lavoie S, Poirier B, Renaud MC, Ruizmangas MG, Sebastianelli A, Roy S, Côté M, Racine MM, Roy MC, Côté N, Brisson C, Charette N, Faucher V, Leblanc J, Dubeau MÈ, Plante M, Desbiens C, Beaumont M, Simard J, Nabi H

A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study

Journal Article

Cancers (Basel), 13 (11), 2021.

Abstract | Links:

Mbuya Bienge C, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Cote L, Paquette JS, Levesque E, Hagan J, Walker MJ, Lapointe J, Dalpe G, Granados Moreno PG, Blackmore K, Wolfson M, Joly Y, Broeders M, Knoppers BM, Chiarelli AM, Simard J, Nabi H

Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada

Journal Article

J Pers Med, 11 (2), 2021.

Abstract | Links:

Cléophat JE, Pelletier S, Déry A, Joly Y, Gagnon P, Marin A, Chiquette J, Gagnon B, Roy L, Bitzas V, Nabi H, Dorval M

Survey of palliative care providers' needs, perceived roles, and ethical concerns about addressing cancer family history at the end of life

Journal Article

Palliat Support Care, 19 (2), 2021.

Abstract | Links:

Labonte M, Guillaumie L, Dionne A, Dorval M, Nabi H, Lemieux J, Provencher L, Lauzier S

Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach

Journal Article

Res Social Adm Pharm, 16 (12), 2020.

Abstract | Links:

104 entries « ‹ 2 of 11 › »
Signaler des ajouts ou des modifications

Active projects

  • Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II), from 2017-11-01 to 2024-03-31
  • Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2024-01-14

Recently finished projects

  • Enjeux de l’intégration de la Médecine de Précision en Oncologie : mieux comprendre pour mieux agir (teMPO), from 2018-07-01 to 2022-06-30
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2023-03-01
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente, from 2020-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery